{"filing":{"accession_number":"0001171843-26-006184","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"f6k_092326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326006184/f6k_092326.htm"},"events":[{"id":34552,"run_id":31797,"accession_number":"0001171843-26-006184","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Optimi announced completion of a cGMP manufacturing batch of psilocybin capsules that will supply both a Health Canada-approved Phase 2 clinical trial for major depressive disorder and commercial supply to Australian licensed clinics. This is a material operational milestone demonstrating the company's ability to manufacture regulated psychedelic products at scale and simultaneously serve clinical and commercial channels, but it does not fit neatly into predefined event categories—it is neither a discrete clinical trial initiation (which would be operational_other anyway), a product approval, nor a financial event. The disclosure is material because it evidences the company's regulatory compliance, manufacturing capability, and revenue-generating commercial operations in Australia.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38304,"accession_number":"0001171843-26-006184","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi announced completion of a cGMP manufacturing batch of psilocybin capsules that will supply both a Health Canada-approved Phase 2 clinical trial for major depressive disorder and commercial supply to Australian licensed clinics. This is a material operational milestone demonstrating the company's ability to manufacture regulated psychedelic products at scale and simultaneously serve clinical and commercial channels, but it does not fit neatly into predefined event categories—it is neither a discrete clinical trial initiation (which would be operational_other anyway), a product approval, nor a financial event. The disclosure is material because it evidences the company's regulatory compliance, manufacturing capability, and revenue-generating commercial operations in Australia.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T17:19:55.755238+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38304,"accession_number":"0001171843-26-006184","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi announced completion of a cGMP manufacturing batch of psilocybin capsules that will supply both a Health Canada-approved Phase 2 clinical trial for major depressive disorder and commercial supply to Australian licensed clinics. This is a material operational milestone demonstrating the company's ability to manufacture regulated psychedelic products at scale and simultaneously serve clinical and commercial channels, but it does not fit neatly into predefined event categories—it is neither a discrete clinical trial initiation (which would be operational_other anyway), a product approval, nor a financial event. The disclosure is material because it evidences the company's regulatory compliance, manufacturing capability, and revenue-generating commercial operations in Australia.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T17:19:55.755238+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-23"}]}